Teknova added to the Nasdaq Biotechnology Index

- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

drug treatments, new vaccines, and molecular diagnostics, revealed that it has joined the Nasdaq Biotechnology Index® (Nasdaq: NBI) on Monday prior to market opening.

The NBI is a leading international biotechnology equity index that monitors the functioning and productivity of Nasdaq-listed biotechnology and pharmaceutical companies. The NBI is extensively watched and monitored by investors and Exchange Traded Funds products globally since it is calculated using a modified capitalization-weighted approach. Teknova qualified as an NBI firm by meeting numerous criteria, such as a minimum market capitalization, an average daily trading volume, and a period of time listed as a public business.

finance.yahoo.com

Stephen Gunstream, President and CEO of Teknova, expressed pride over the company’s accomplishments. He said, “The Teknova team has successfully executed on several important milestones since our Initial Public Offering in June 2021, and I’m proud of their commitment to our mission of accelerating the development and commercialization of next generation therapies, vaccines, and diagnostics. We are honored to join the NBI, which we believe validates our team’s hard work and progress in delivering value to all our stakeholders”.

By supplying specialized products and reagents for bioprocessing, bioproduction, and molecular diagnostics, Teknova is accelerating clinical advancements in the life sciences.  Teknova’s innovative techniques support the manufacturing and delivery of high-quality, custom-made-to-order goods quickly and at scale throughout all stages of development, including marketing.

With an emphasis on agility and customization, Teknova develops and manufactures research-grade and GMP products such as cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a variety of well-known and emerging applications such as cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology.

A Personal Note from the Publisher" Small photo of you, with your signature beneath

A Personal Note from the Publisher

My dear friend, thank you for your time with us today. This site was built for you, the members of the Commonwealth Family, and nothing matters more to me than hearing your voice and feedback.

What did you make of this article? Did it inform you, challenge you, or leave you wanting more?

Please tell me. I read your replies personally and they help shape everything we publish.

With warmest wishes,
Hon. Nirj Deva
Founder and Publisher.

Free, always. We'll never sell your details.

spot_img

Hot this week

India’s Gold Revolution: You Can Now Own Gold Without Ever Holding It—What Is Changing?

MUMBAI, INDIA — 20 NOVEMBER 2026 People in India have...

Malta’s New Tourist Tax Set to Exceed Rates in Competing Mediterranean Destinations

Travellers planning a holiday in Malta will soon face...

TSMC Tightens Chip Manufacturing Rules for Chinese Companies After New US Export Controls

The world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co...

Jamaica and the United States Sign Customs Agreement to Bolster Border Security

Jamaica and the United States have signed a new...

The Flight Was Over, But the Danger Wasn’t: Why Two Virgin Australia Pilots Refused to Fly Again

ADELAIDE, AUSTRALIA — 20 NOVEMBER 2026 It is possible for...
- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

Related Articles

- Advertisement -sitaramatravels.comsitaramatravels.com

Popular Categories